A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction.

ABSTRACT:

Aims

The PARADIGM-HF and PARAGON-HF trials tested sacubitril/valsartan against active controls given renin-angiotensin system inhibitors (RASi) are ethically mandated in heart failure (HF) with reduced ejection fraction and are used in the vast majority of patients with HF with preserved ejection fraction. To estimate the effects of sacubitril/valsartan had it been tested against a placebo control, we made indirect comparisons of the effects of sacubitril/valsartan with putative placebos in HF across the full range of left ventricular ejection fraction (LVEF).

Methods and results

We analysed patient-level data from the PARADIGM-HF and PARAGON-HF trials (n = 13 194) and the CHARM-Alternative and CHARM-Preserved trials (n = 5050, candesartan vs. placebo). The rate ratio (RR) o

SUBMITTER: Vaduganathan M 

PROVIDER: S-EPMC7327532 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature